In 86 migraine patients (40 randomised to erenumab 70 mg or placebo, 46 given open-label erenumab 140 mg), no quantitative sensory testing parameter changed after treatment at the forehead or forearm, unlike reported effects of galcanezumab.
RCTn = 86 patients
Peng et al. Anti-CGRP receptor antibodies do not modulate trigeminal pain processing: indication for distinct mechanisms of CGRP pathway blockade